Related Experiment Video
Updated: Jul 6, 2026
11:19
Novel RNA-Binding Proteins Isolation by the RaPID Methodology
Published on: September 30, 2016
Nelarabine.
Mark Sanford1, Katherine A Lyseng-Williamson
1Wolters Kluwer Health Adis, Auckland, New Zealand. demail@adis.co.nz
Drugs
|March 6, 2008
Summary
Nelarabine, an anticancer drug, shows efficacy in T-cell leukaemias and lymphomas. It induces complete responses in some patients resistant to prior treatments, though neurological side effects require careful monitoring.
Area of Science:
- Pharmacology
- Oncology
- Molecular Biology
Background:
- Nelarabine is an anticancer prodrug.
- It is metabolized to arabinofuranosylguanine triphosphate (ara-GTP).
- Ara-GTP inhibits DNA synthesis and induces cell death.
Purpose of the Study:
- To evaluate the efficacy and safety of nelarabine.
- To assess nelarabine's response in relapsed or refractory T-cell malignancies.
- To analyze survival outcomes and adverse events.
Main Methods:
- Clinical trial data analysis.
- Evaluation of complete response rates.
- Assessment of overall survival and adverse events.
Main Results:
- Nelarabine induced complete responses in approximately one-fifth of heavily pretreated paediatric and adult patients with T-cell acute lymphoblastic leukaemia or T-cell lymphoblastic lymphoma.
- Median overall survival was 13.1 weeks for paediatric and 20.6 weeks for adult patients.
- Neurological events were the most significant adverse events, potentially severe and irreversible.
Conclusions:
- Nelarabine demonstrates activity in relapsed/refractory T-cell leukaemias and lymphomas.
- The drug offers a treatment option for patients with limited prior therapeutic success.
- Careful monitoring for neurological toxicity is crucial during nelarabine treatment.
More Related Videos
Related Concept Videos
01:30Nucleophilic Aromatic Substitution: Addition–Elimination (SNAr)
Nucleophilic substitution in aromatic compounds is feasible in substrates bearing strong electron-withdrawing substituents positioned ortho or para to the leaving group. The reaction proceeds via two steps: the addition of the nucleophile and the elimination of the leaving group.
The reaction begins with an attack of the nucleophile on the carbon that holds the leaving group. This results in the delocalization of the π electrons over the ring carbons. The resonance interaction between the...
The reaction begins with an attack of the nucleophile on the carbon that holds the leaving group. This results in the delocalization of the π electrons over the ring carbons. The resonance interaction between the...
01:14Rab Proteins
Rab proteins constitute the largest family of monomeric GTPases, of which 70 members are present in humans. Rab proteins and their effectors regulate consecutive stages of vesicle transport such as vesicle transport, docking, and fusion to the correct recipient membrane.
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:25Rab Cascades
Rab GTPases act in a regulated cascade during membrane fusion, helping the lipid bilayers mix. The Rab family of proteins are active when bound to GTP, and inactive when bound to GDP. Hence, they act as guanine nucleotide-dependent molecular switches. Rab-GTP recognizes and binds to long or short-range tethering proteins to capture the target vesicle. These tethers coordinate with SNAREs on the vesicle and the target membrane to assemble the trans SNARE complex that locks the mixing bilayers.
02:53Ribosomal RNA Synthesis
Ribosome synthesis is a highly complex and coordinated process involving more than 200 assembly factors. The synthesis and processing of ribosomal components occurs not only in the nucleolus but also in the nucleoplasm and the cytoplasm of eukaryotic cells.
Ribosome biogenesis begins with the synthesis of 5S and 45S pre-rRNAs by distinct RNA polymerases. The primary transcripts are extensively processed and modified before they are bound and folded by ribosomal proteins and assembly factors,...
Ribosome biogenesis begins with the synthesis of 5S and 45S pre-rRNAs by distinct RNA polymerases. The primary transcripts are extensively processed and modified before they are bound and folded by ribosomal proteins and assembly factors,...
02:53Ribosomal RNA Synthesis
Ribosome synthesis is a highly complex and coordinated process involving more than 200 assembly factors. The synthesis and processing of ribosomal components occurs not only in the nucleolus but also in the nucleoplasm and the cytoplasm of eukaryotic cells.
Ribosome biogenesis begins with the synthesis of 5S and 45S pre-rRNAs by distinct RNA polymerases. The primary transcripts are extensively processed and modified before they are bound and folded by ribosomal proteins and assembly factors,...
Ribosome biogenesis begins with the synthesis of 5S and 45S pre-rRNAs by distinct RNA polymerases. The primary transcripts are extensively processed and modified before they are bound and folded by ribosomal proteins and assembly factors,...